Institute for Clinical and Experimental Medicine is the largest Czech medical research and clinical hospital located in Prague–Krč. It is directly managed the Ministry of Health and it was established in 1971 as a part of nearby Thomayer Hospital.

There are 312 (2020) beds in Institut klinicke a experimentalni mediciny.

During the past decade, Institut klinicke a experimentalni mediciny conducted 42 clinical trials. In the 10-year time frame, 42 clinical trials started and 18 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 11 clinical trials were completed. i.e. 57.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut klinicke a experimentalni mediciny" #1 sponsor was "Bayer" with 6 trials, followed by "Celgene" with 5 trials sponsored, "Pfizer" with 5 trials sponsored, "Medtronic Cardiac Rhythm and Heart Failure" with 3 trials sponsored and "Reata Pharmaceuticals, Inc." with 3 trials sponsored. Other sponsors include 28 different institutions and companies that sponsored additional 33 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut klinicke a experimentalni mediciny" #1 collaborator was "Cyril and Methodius University in Skopje" with 1 trials as a collaborator, "Diabetes Vascular Research Foundation Hoogeveen" with 1 trials as a collaborator, "Diabetologen Hessen" with 1 trials as a collaborator, "Duke University" with 1 trials as a collaborator and "European Commission" with 1 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "Institut klinicke a experimentalni mediciny" are "Ulcerative Colitis" (6 trials), "Crohn Disease" (4 trials), "Crohn's Disease" (4 trials), "Heart Failure" (4 trials) and "Atrial Fibrillation" (3 trials). Many other conditions were trialed in "Institut klinicke a experimentalni mediciny" in a lesser frequency.

Most popular intervention types in "Institut klinicke a experimentalni mediciny" are "Drug" (39 trials), "Other" (12 trials), "Device" (11 trials), "Biological" (4 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Ozanimod" (3 trials), "Apixaban" (2 trials), "Apixaban matching placebo" (2 trials) and "BAY2433334" (2 trials). Other intervention names were less common.

The vast majority of trials in "Institut klinicke a experimentalni mediciny" are 55 trials for "All" genders.

Currently, there are NaN active trials in "Institut klinicke a experimentalni mediciny". undefined are not yet recruiting, 14 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in Institut klinicke a experimentalni mediciny, 1 suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Institut klinicke a experimentalni mediciny, 3 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 10 trials that are defined as “Not Applicable".